Compare GSK plc (GSK) vs Oracle Corporation (ORCL) Price & Performance

GSK plcTrade

Oracle CorporationTrade

Price performance (Past 24H)

Key statistics

GSK plc vs Oracle Corporation — how do they compare? GSK plc trades at $51.15 (market cap $102.60B), while Oracle Corporation trades at $152.81 (market cap $419.05B). The key difference: Oracle Corporation is far larger — about 4.1× GSK plc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.

	GSK	ORCL
Market Cap	$102.60B	$419.05B
Sector	Health	Technology
52-Week High	$61.18	$328.33
52-Week Low	$38.22	$114.99
Enterprise Value	$123.04B	$548.30B
Dividend Yield	3.57%	1.37%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.

Oracle Corporation

Oracle Corporation (ORCL) trades at $151.04, up 2.79% with strong technical momentum. The stock shows robust fundamentals with 21.67% net profit margin and consistent earnings beats in recent quarters. Oracle's AI infrastructure positioning and partnership with OpenAI have driven investor optimism, though RSI levels suggest potential overbought conditions. The company maintains solid cash flow generation with $20.82B from operations in 2025.

Oracle presents a compelling growth story with AI-driven revenue acceleration and strong analyst support (65% buy ratings). Key risks include high valuation multiples and significant debt load. The consensus price target of $252.44 implies substantial upside, but investors should monitor execution on AI investments and competitive pressures in cloud infrastructure.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GSK

Trump orders splitting MMR vaccine into three shots despite no scientific support and expert criticism.CNBC · 1 day agoBearish Theravance Biopharma to be acquired by Zymeworks in H2 2026; Q2 revenue up 11% on YUPELRI growth and cost cuts.PRNewsWire · 2 days agoBullish View details →

ORCL

Oracle and Supermicro report strong AI-driven growth but face cash flow challenges.24/7 Wall Street · 9 hours agoNeutral Quantinuum reports 279% revenue growth and forms key alliances, boosting quantum computing market position.Alex Lavoie · 10 hours agoBullish Microsoft shares rise after strong Q4, with $604 price target and 20% upside forecast.24/7 Wall Street · 10 hours agoBullish View details →

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

About Oracle Corporation

Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.